The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline‐concordant lung cancer staging

Abstract Accurate staging improves lung cancer survival by increasing the chances of delivering stage‐appropriate therapy. However, there is underutilization of, and variability in, the use of guideline‐recommended diagnostic tests used to stage lung cancer. Consequently, the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) convened the Triage for Appropriate Treatment Task Group—a multidisciplinary expert and stakeholder panel—to identify knowledge and/or resource gaps contributing to guideline‐discordant staging and make recommendations to overcome these gaps. The task group determined the following: Gap 1: facilitators of and barriers to guideline‐concordant staging are incompletely understood; Recommendation 1: identify facilitators of and barriers to guideline‐concordant lung cancer staging; Gap 2: the level of evidence supporting staging algorithms is low‐to‐moderate; Recommendation 2: prioritize comparative‐effectiveness studies evaluating lung cancer staging; Gap 3: guideline recommendations vary across professional societies; Recommendation 3: harmonize guideline recommendations across professional societies; Gap 4: existing databases do not contain sufficient information to measure guideline‐concordant staging; Recommendation 4: augment existing databases with the information required to measure guideline‐concordant staging; Gap 5: health systems do not have a performance feedback mechanism for lung cancer staging; Recommendation 5: develop and implement a performance feedback mechanism for lung cancer staging; Gap 6: patients rarely self‐advocate for guideline‐concordant staging; Recommendation 6: increase opportunities for patient self‐advocacy for guideline‐concordant staging; and Gap 7: current health policies do not motivate guideline‐concordant lung cancer staging; Recommendation 7: organize a representative working group under the ACS NLCRT that promotes policies that motivate guideline‐concordant lung cancer staging. Plain language summary Staging—determining the degree of cancer spread—is important because it helps clinicians choose the best cancer treatment. Receiving the best cancer treatment leads to the best possible patient outcomes. Practice guidelines are intended to help clinicians stage patients with lung cancer. However, lung cancer staging in the United States often varies from practice guideline recommendations. This report identifies seven opportunities to improve lung cancer staging.